1. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with standard of care therapeutic agents for the treatment of breast cancer;Abrams;Mol. Cancer Ther.,2003
2. Safety, pharmacokinetic, and antitumor activity of SU11248 a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer;Faivre;J. Clin. Oncol.,2006
3. Sunitinib malate for the treatment of solid tumours: a review of current clinical data;Motzer;Expert Opin. Investig. Drugs,2006
4. Sunitinib malate;Atkins;Nat. Rev. Drug Discov.,2006
5. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship;Mendel;Clin. Cancer Res.,2003